A 21-year-old Caucasian male diagnosed with AML M7 (FAB) and trilineal dysplasia, refractory to first-line chemotherapy (PETHEMA), underwent an unrelated donor, BM, myeloablative, allogeneic hematopoietic SCT (HSCT) in CR after salvage chemotherapy with three cycles of FLAT (fludarabine, ARA-C and topotecan).
Post-transplant, he developed acute grade III (skin and gut) GVHD, treated with tacrolimus and methylprednisolone, achieving complete resolution on day þ 28. On day þ 113, he presented with symptoms suggestive of a late onset digestive aGVHD that was resolved with oral and topical steroids (prednisone and beclomethasone, respectively). At 1-year post transplant, similar symptoms affecting his gut and skin, together with eosinophilia, were interpreted as moderate extensive chronic GVHD. Initially, he was treated with steroids and had a favorable response, but recurrent symptoms after 8 months did not respond either to pravastatin and high-dose steroids or to rapamycin (2-years post transplant) and prednisone (after 1 month). Finally, complete resolution of signs and symptoms of cGVHD affecting his digestive tract and oral mucosae was achieved with four courses of standard dose, single-agent Rituximab. Skin and nail involvement did not improve with the treatment.
At 3 years after transplantation, surgical pain after an avascular hip-head-necrosis intervention was managed with dexketoprofen, tramadol and cefazoline. After 10 days, the patient developed a macular erythema involving his trunk, face and upper and lower limbs that was interpreted as extensive severe cGVHD (cutaneous (grade 3), digestive tract (grade 1) with persistent nail (grade 2) and oral mucosal involvement (grade 2) cGVHD). He received two courses of mesenchymal stromal cells (MSCs) as treatment. At 5 weeks after surgery, he was admitted to hospital with a fever of surgical-wound origin as first suspicion. He was treated with levofloxacin. A few hours later, he presented with sudden acute vision loss and photopsiae, lasting for 10 min and without neurological or ophthalmological clinical findings (a CT of the brain was normal). The persistence of fever and the growth of Ps. aeruginosa in wound swabs and S. epidermidis in blood cultures, prompted a switch from levofloxacin to meropenem, teicoplanin and amikacin after 24 h. After 2 days, he was presented with a generalized convulsion followed by a 35-min-long epileptic status with neurological sequelae in the following 24-48 h, without acute findings in a brain CT. Empirical antiviral treatment with acyclovir was started in conjunction with levetiracetam as anticonvulsant. Meropenem was switched to piperacillin-tazobactam and linezolid because of suspected neurotoxicity.
An MRI scan showed a hyperintense lesion encompassing the temporal lobe of the right hemisphere, hippocampal area and hippocampus suggestive of viral encephalitis. HSV PCR was positive in spinal fluid, and neurological signs and symptoms improved under treatment (antibiotic, antiviral, antifungal and anticonvulsant) but fever spikes persisted. Because of the isolation of Candida krusei and C. tropicalis in blood cultures, he began antifungal treatment with caspofungin.
The extensive skin involvement (90% of the total body surface), considered as extensive severe GVHD, progressed to denudation and epidermolysis at 10 days after his admission without response to occlusive cures and i.v. high-dose steroid treatment. Differential diagnosis of a punch-biopsy of the skin included GVHD and toxicodermia, but no definite histological diagnosis could be made.
Because of the worsening symptoms and the clinical suspicion of a severe drug reaction, all drugs were switched to different molecules. He also received a single high dose of i.v. Igs. He presented with odynodysphagia due to mucosal involvement, which needed total parenteral nutrition. During his hospitalization, no renal damage was documented, but significant eosinophilia and low inmunoglobulin levels were always present. A mild liver damage, without jaundice, was seen. Because of the life-threatening skin involvement, the patient was transferred to a specialist burns unit, but died after 24 h because of multiorgan failure.
DRESS syndrome is a severe, acute drug reaction, 1 defined by the presence of fever, cutaneous eruption and systemic findings, including enlarged lymph nodes, abnormal liver function, renal impairment, pulmonary or cardiac infiltrates and hematological abnormalities (mainly hypereosinophilia and lymphocytosis). Clinical manifestations typically occur within 2-6 weeks of the initiation of drug (Table 1 ) therapy, and in most cases, resolve when the drug is discontinued, without sequelae; however, a fatal outcome has been reported in 10-40% of cases. 2 The differential diagnosis includes acute viral infections, idiopathic hypereosinophilic syndrome and lymphoma. 2, 3 In this case, the differential diagnosis with cutaneous GVHD was the most difficult issue. The two entities share several characteristics, including skin manifestations and liver abnormalities. The limited utility of skin biopsies to differentiate GVHD from drug hypersensitivity reactions under most circumstances is well known. 4 Furthermore, several authors have suggested a possible interaction between DRESS and reactivation or primary infection with HHV6, 5, 6 and other herpesviruses (EBV, CMV and HHV7) can be reactivated during the course of DIHS, as has been demonstrated in GVHD. 7 Our patient suffered a reactivation of HHV causing a viral encephalitis at 4 weeks after the surgery. 8 The differential diagnosis between a severe GVHD and DRESS could be on the basis of gut involvement and jaundice, neither of which is usual in DRESS. Furthermore, a prominent eosinophilia is more characteristic of DRESS. In our case, the patient met all diagnostic criteria for DRESS established by a Japanese consensus group 9 ( Table 2 ). The initial assumption of severe GVHD could have delayed the withdrawal of causative drugs. Although the disease can progress in severity despite withdrawal of injurious drugs, this is considered important in order to avoid further activation of the immune system. Our patient received high doses of Prednisone to treat GVHD, but in spite of this the disease continued progressing, as the offending drugs were not removed. In addition, as new sensitizations can appear during the evolution of DRESS, this possibility cannot be discounted in our patient. In addition, partly due to the relatively long latency after initiation and the long duration after cessation of the culprit drug, the symptoms are often not recognized as drug related. 8 In conclusion, DRESS should always be borne in mind in polymedicated patients, particularly in those with severe GVHD. A high suspicion index is essential in such patients.
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The diagnosis is confirmed by the presence of the seven criteria mentioned above (typical DISH/DRESS) or five (1-5) of the seven (atypical DISH/DRESS).
